Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Sold by Centiva Capital LP

Centiva Capital LP trimmed its stake in Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Free Report) by 69.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 43,403 shares of the biotechnology company's stock after selling 96,847 shares during the quarter. Centiva Capital LP owned approximately 0.75% of Atara Biotherapeutics worth $353,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in Atara Biotherapeutics in the 2nd quarter valued at about $53,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Atara Biotherapeutics during the second quarter worth about $79,000. FMR LLC lifted its stake in shares of Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company's stock valued at $204,000 after buying an additional 7,381 shares during the period. Finally, Vestal Point Capital LP boosted its position in Atara Biotherapeutics by 11.3% during the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company's stock worth $1,014,000 after acquiring an additional 12,677 shares during the last quarter. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have weighed in on ATRA shares. Canaccord Genuity Group boosted their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. HC Wainwright reiterated a "neutral" rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. Mizuho upgraded Atara Biotherapeutics from a "neutral" rating to an "outperform" rating and lowered their price target for the company from $25.00 to $18.00 in a report on Friday, August 16th. Finally, TD Cowen upgraded shares of Atara Biotherapeutics to a "strong-buy" rating in a report on Friday, November 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Atara Biotherapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $16.67.

Atara Biotherapeutics Stock Down 5.0 %

Shares of Atara Biotherapeutics stock traded down $0.63 during trading hours on Tuesday, hitting $12.19. The company's stock had a trading volume of 48,370 shares, compared to its average volume of 105,355. The company has a market capitalization of $70.19 million, a PE ratio of -0.47 and a beta of 0.55. The business has a fifty day moving average of $10.33 and a 200 day moving average of $9.76. Atara Biotherapeutics, Inc. has a 1-year low of $6.50 and a 1-year high of $39.50.

Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating the consensus estimate of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analysts' expectations of $23.00 million. During the same period last year, the business earned ($16.50) earnings per share. On average, sell-side analysts anticipate that Atara Biotherapeutics, Inc. will post -12.12 earnings per share for the current fiscal year.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.